Notable Ups And Down: Regions Financial Corporation (NYSE:RF), Paramount Gold and Silver (NYSEMKT:PZG), Golar LNG (NASDAQ:GLNG), Onconova Therapeutics (NASDAQ:ONTX), Cubist Pharmaceuticals (NASDAQ:CBST)


Stock analysts at Guggenheim started coverage on shares of Regions Financial Corp (NYSE:RF) in a report issued on Monday, TheFlyOnTheWall.com reports. The firm set a “neutral” rating on the stock. Regions Financial Corporation (NYSE:RF) in last trading activity advanced 0.10% to close at $10.45. Company weekly performance is 4.40% while its quarterly performance stands at 1.55%. Regions Financial Corporation (NYSE:RF) is -8.12% away from its 52 week high.

On Dec 17, Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Paramount Gold and Silver Corp. (NYSE:PZG), breached their fiduciary duties in connection with the proposed sale of the company to Coeur Mining, Inc. On last trading day Paramount Gold and Silver Corp. (NYSEMKT:PZG) decreased -1.05% to close at $0.94. Its volatility for the week is 13.70% while volatility for the month is 9.62%. PZG’s EPS growth for past 5 years was 10.20%. Paramount Gold and Silver Corp. (NYSEMKT:PZG) monthly performance is 38.72%.

On Dec 15, Golar LNG Ltd. (NASDAQ:GLNG) announced that it has entered into an agreement to sell its ownership interests in the companies that will own and operate the floating storage and regasification unit (“FSRU”) Golar Eskimo (“Eskimo”) to Golar LNG Partners L.P. (“Golar Partners”) for a price of USD 390 million. The transaction is subject to the satisfaction of certain closing conditions which is expected to be finalized in January 2015. On last trading day Golar LNG Ltd. (NASDAQ:GLNG) advanced 3.25% to close at $36.23. Its volatility for the week is 7.80% while volatility for the month is 7.79%. GLNG’s sales growth for past 5 years was -15.60% and its EPS growth for past 5 years was 64.40%. Golar LNG Ltd. (NASDAQ:GLNG) monthly performance is -28.02%.

Onconova Therapeutics, Inc. (NASDAQ:ONTX), presented its data from clinical trials of rigosertib in myelodysplastic syndromes (MDS) and non-proliferative acute myeloid leukemia (AML) at the 56th American Society of Hematology (ASH), at Annual Meeting in San Francisco, California, on December 6-9, 2014. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has 0.10% insider ownership while its institutional ownership stands at 9.50%. In last trading activity company’s stock closed at $3.99.

Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) said Friday that the U.S. Food and Drug Administration has approved Zerbaxa for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections caused by designated susceptible Gram-negative bacteria. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) in last trading activity increased 0.92% to close at $98.67. Company weekly performance is 2.45% while its quarterly performance stands at 49.03%. Cubist Pharmaceuticals Inc. (NASDAQ:CBST) is -2.34% away from its 52 week high.


Leave a Reply

Your email address will not be published. Required fields are marked *